|
市場調査レポート
商品コード
1085375
糖尿病デバイス・治療薬の世界市場：カテゴリー別（診断とモニタリング、治療）、疾患タイプ別、地域別－規模、シェア、展望、機会分析（2022年～2028年）Diabetes Devices and Drugs Market, By Category (Diagnosis and Monitoring, Therapeutics ), By Disease Type, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 |
||||||
|
|
|||||||
 ● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。 |
|||||||
価格
| 糖尿病デバイス・治療薬の世界市場：カテゴリー別（診断とモニタリング、治療）、疾患タイプ別、地域別－規模、シェア、展望、機会分析（2022年～2028年） |
|
出版日: 2022年05月29日
発行: Coherent Market Insights
ページ情報: 英文 183 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
概要
新興国における糖尿病診断・治療に関する認知度の低さが、糖尿病デバイス・治療薬市場の成長を阻害すると予想されます。
当レポートでは、世界の糖尿病デバイス・治療薬市場について調査しており、市場展望、市場力学、市場分析、競合情勢など、包括的な情報を提供しています。
目次
第1章 調査目的・前提条件
- 調査目的
- 仮定
- 略語
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
- 市場の内訳：カテゴリー別
- 市場の内訳：疾患タイプ別
- コヒーレントオポチュニティマップ（COM）
第3章 市場力学、規制、および動向分析
- 市場力学
- 促進要因
- 抑制要因
- 市場機会
- 影響分析
- 主な開発
- 規制シナリオ
- PEST分析
第4章 世界の糖尿病デバイス・治療薬市場：カテゴリー別（100万米ドル）（2017年～2028年）
- イントロダクション
- 市場シェア分析（％）（2022年～2028年）
- 前年比成長分析（2017年～2028年）
- セグメント動向
- 診断とモニタリング
- イントロダクション
- 市場規模と予測、および前年比成長率（100万米ドル）（2017年～2028年）
- セグメント動向
- 血糖モニタリングデバイス
- その他の試験装置
- 糖尿病モニタリングのためのソフトウェアプログラム
- 人工膵臓
- 治療
- イントロダクション
- 市場規模と予測、および前年比成長率（100万米ドル）（2017年～2028年）
- セグメント動向
- インスリン
- インスリン送達
- 経口血糖降下薬
- 細胞治療
第5章 世界の糖尿病デバイス・治療薬市場：疾患タイプ別（100万米ドル）（2017年～2028年）
- イントロダクション
- 市場シェア分析（％）（2022年～2028年）
- 前年比成長分析（2017年～2028年）
- セグメント動向
- 2型糖尿病
- イントロダクション
- 市場規模と予測、および前年比成長率（100万米ドル）（2017年～2028年）
- セグメント動向
- 1型糖尿病
- イントロダクション
- 市場規模と予測、および前年比成長率（100万米ドル）（2017年～2028年）
- セグメント動向
第6章 世界の糖尿病デバイス・治療薬市場：地域別（100万米ドル）（2017年～2028年）
- イントロダクション
- 市場シェア分析（％）（2022年～2028年）
- 前年比成長分析（2017年～2028年）
- セグメント動向
- 北米
- 米国
- カナダ
- 欧州
- 英国
- ドイツ
- イタリア
- フランス
- スペイン
- ロシア
- その他の欧州
- アジア太平洋
- 中国
- インド
- 日本
- ASEAN諸国
- オーストラリア
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- その他のラテンアメリカ
- 中東
- GCC諸国
- イスラエル
- その他の中東
- アフリカ
- 北アフリカ
- 中央アフリカ
- 南アフリカ
第7章 競合情勢
- 企業プロファイル
- Abbott Laboratories
- Bristol-Myers Squibb
- DexCom, Inc.
- Eli Lilly and Company
- Companion Medical
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals
- Johnson &Johnson
- Lupin Ltd.
- F. Hoffmann-La Roche AG
- Sanofi
第8章 セクション
- 参考文献
- 調査手法
- 当社と営業窓口について
目次
Product Code: CMI3857
Diabetes devices and drugs (diagnosis, monitoring and therapeutics) consists of diabetes management right from diagnosis, monitoring, till treatment. Diabetes is characterized by high presence of blood glucose, also called blood sugar, in the body. There are three main types of diabetes: type 1, type 2, and gestational diabetes. Oral glucose tolerance testing and hemoglobin A1c (HbA1c) testing are some of the tests used in the diagnosis of the chronic condition. Treatment options include use of insulin, oral hypoglycemic agents, and others.
Restraints of the Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market
Lack of awareness about diabetes diagnostics and treatment, especially in emerging economies, is expected to hinder growth of the global diabetes devices and drugs (diagnosis, monitoring, and therapeutics) market. Moreover, recall of diabetes drugs is also expected to limit growth of the market.
Key features of the study:
- This report provides in-depth analysis of the global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, and Sanofi.
- Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global diabetes devices and drugs (diagnosis, monitoring and therapeutics) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
- Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Category:
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Other Testing Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
- Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Disease Type:
- Type 2 Diabetes
- Type 1 Diabetes
- Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Geography:
- North America
- By Category
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Other Testing Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
- Diagnosis and Monitoring
- By Disease Type
- Type 2 Diabetes
- Type 1 Diabetes
- By Country:
- U.S.
- Canada
- Europe
- By Category
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Other Testing Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
- Diagnosis and Monitoring
- By Disease Type
- Type 2 Diabetes
- Type 1 Diabetes
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Category
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Other Testing Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
- Diagnosis and Monitoring
- By Disease Type
- Type 2 Diabetes
- Type 1 Diabetes
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Category
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Other Testing Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
- Diagnosis and Monitoring
- By Disease Type
- Type 2 Diabetes
- Type 1 Diabetes
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East:
- By Category
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Other Testing Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
- Diagnosis and Monitoring
- By Disease Type
- Type 2 Diabetes
- Type 1 Diabetes
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Category
- Diagnosis and Monitoring
- Blood Glucose Monitoring Devices
- Other Testing Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Therapeutics
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
- Diagnosis and Monitoring
- By Disease Type
- Type 2 Diabetes
- Type 1 Diabetes
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Abbott Laboratories *
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Bristol-Myers Squibb
- DexCom, Inc.
- Eli Lilly and Company
- Companion Medical
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals
- Johnson & Johnson
- Lupin Ltd.
- F. Hoffmann-La Roche AG
- Sanofi
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Category
- Market Snippet, By Disease Type
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Regulatory Scenario
- PEST Analysis
4. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Category, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Diagnosis and Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
- Blood Glucose Monitoring Devices
- Other Testing Devices
- Software Programs for Diabetes Monitoring
- Artificial Pancreas
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
- Insulin
- Insulin Delivery
- Oral Hypoglycemic Agents
- Cell Therapies
5. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Disease Type, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
- Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Segment Trends
6. Global Diabetes Devices and Drugs (Diagnosis, Monitoring and Therapeutics) Market, By Regions, 2017 - 2028 (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Company Profiles
- Abbott Laboratories
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- DexCom, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Companion Medical
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
8. Section
- References
- Research Methodology
- About us and Sales Contact
